Literature DB >> 22611040

Patients transplanted for nonalcoholic steatohepatitis are at increased risk for postoperative cardiovascular events.

Lisa B Vanwagner1, Manali Bhave, Helen S Te, Joe Feinglass, Lisa Alvarez, Mary E Rinella.   

Abstract

UNLABELLED: Nonalcoholic steatohepatitis (NASH) is an independent predictor of coronary artery disease (CAD). Our aim was to compare the incidence of cardiovascular (CV) events between patients transplanted for NASH and alcohol (ETOH)-induced cirrhosis. This is a retrospective cohort study (August 1993 to March 2010) of 242 patients (115 NASH and 127 ETOH) with ≥12 months follow-up after liver transplantation (LT). Those with hepatocellular carcinoma or coexisting liver diseases were excluded. Kaplan-Meier's and Cox's proportional hazard analyses were conducted to compare survival. Logistic regression was used to calculate the likelihood of CV events, defined as death from any cardiac cause, myocardial infarction, acute heart failure, cardiac arrest, arrhythmia, complete heart block, and/or stroke requiring hospitalization <1 year after LT. Patients in the NASH group were older (58.4 versus 53.3 years) and were more likely to be female (45% versus 18%; P < 0.001). They were more likely to be morbidly obese (32% versus 9%), have dyslipidemia (25% versus 6%), or have hypertension (53% versus 38%; P < 0.01). On multivariate analysis, NASH patients were more likely to have a CV event <1 year after LT, compared to ETOH patients, even after controlling for recipient age, sex, smoking status, pretransplant diabetes, CV disease, and the presence of metabolic syndrome (26% versus 8%; odds ratio = 4.12; 95% confidence interval = 1.91-8.90). The majority (70%) of events occurred in the perioperative period, and the occurrence of a CV event was associated with a 50% overall mortality. However, there were no differences in patient, graft, or CV mortality between groups.
CONCLUSIONS: CV complications are common after LT, and NASH patients are at increased risk independent of traditional cardiac risk factors, though this did not affect overall mortality.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Year:  2012        PMID: 22611040     DOI: 10.1002/hep.25855

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  60 in total

Review 1.  Lipoprotein metabolism, dyslipidemia, and nonalcoholic fatty liver disease.

Authors:  David E Cohen; Edward A Fisher
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

2.  Use of Six-Minute Walk Test to Measure Functional Capacity After Liver Transplantation.

Authors:  Lisa B VanWagner; Sarah Uttal; Brittany Lapin; Joshua Lee; Amanda Jichlinski; Tanvi Subramanian; Madeleine Heldman; Brian Poole; Eduardo Bustamante; Suvai Gunasekaran; Christopher S Tapia; Annapoorani Veerappan; She-Yan Wong; Josh Levitsky
Journal:  Phys Ther       Date:  2016-04-07

Review 3.  Carbohydrate intake and nonalcoholic fatty liver disease: fructose as a weapon of mass destruction.

Authors:  Metin Basaranoglu; Gokcen Basaranoglu; Elisabetta Bugianesi
Journal:  Hepatobiliary Surg Nutr       Date:  2015-04       Impact factor: 7.293

4.  A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: The CAR-OLT score.

Authors:  Lisa B VanWagner; Hongyan Ning; Maureen Whitsett; Josh Levitsky; Sarah Uttal; John T Wilkins; Michael M Abecassis; Daniela P Ladner; Anton I Skaro; Donald M Lloyd-Jones
Journal:  Hepatology       Date:  2017-11-06       Impact factor: 17.425

5.  Outcome of Liver Transplant Recipients With Revascularized Coronary Artery Disease: A Comparative Analysis With and Without Cardiovascular Risk Factors.

Authors:  Sanjaya K Satapathy; Jason M Vanatta; Ryan A Helmick; Albert Flowers; Satish K Kedia; Yu Jiang; Bilal Ali; James Eason; Satheesh P Nair; Uzoma N Ibebuogu
Journal:  Transplantation       Date:  2017-04       Impact factor: 4.939

6.  Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis.

Authors:  Lisa B VanWagner; Brittany Lapin; Anton I Skaro; Donald M Lloyd-Jones; Mary E Rinella
Journal:  Liver Int       Date:  2015-06-03       Impact factor: 5.828

Review 7.  Role of cardiovascular intervention as a bridge to liver transplantation.

Authors:  Zankhana Raval; Matthew E Harinstein; James D Flaherty
Journal:  World J Gastroenterol       Date:  2014-08-21       Impact factor: 5.742

Review 8.  Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?

Authors:  François Cauchy; David Fuks; Alban Zarzavadjian Le Bian; Jacques Belghiti; Renato Costi
Journal:  World J Hepatol       Date:  2014-05-27

Review 9.  Nonalcoholic Fatty Liver Disease-Evidence for a Thrombophilic State?

Authors:  Margaret Spinosa; Jonathan G Stine
Journal:  Curr Pharm Des       Date:  2020       Impact factor: 3.116

Review 10.  Extra-Hepatic Manifestations of Nonalcoholic Fatty Liver Disease: A Review.

Authors:  Raseen Tariq; Page Axley; Ashwani K Singal
Journal:  J Clin Exp Hepatol       Date:  2019-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.